Loading stock data…
CRVO
$3.71+0.02 (+0.54%)
Market ClosedLast close May 1
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CervoMed Inc. in the Healthcare sector is trading at $3.71. The stock is currently near its 52-week low of $3.51, remaining 46.8% below its 200-day moving average. Technical signals show oversold RSI of 27 and bearish MACD signal, explaining why CRVO maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 27) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.71
Potential Upside
5%
Whystock Fair Value$3.90
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$22.14+496.8%
Range$11.00 – $31.00
Fundamentals
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosse...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$36.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-5.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-147.98%
Volume
Today's trading volume
59,442
Recent News
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)
CervoMed Inc. (NASDAQ:CRVO) earns a place on our top 10 stocks under $5 that could triple. On March 17, 2026, CervoMed Inc. (NASDAQ:CRVO) announced results for the fourth quarter and full year 2025. The company highlighted advancements in its neflamapimod program for dementia with Lewy bodies (DLB). CervoMed Inc. (NASDAQ:CRVO) further reported favorable Phase 2b […]
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates
CERVOMED INC (CRVO) delivered earnings and revenue surprises of -10.93% and -98.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
PHAR heads into Q4 results, with Ruconest and Joenja sales in focus, pipeline updates looming, and investors eyeing clarity on key regulatory setbacks.
Pleasing Signs As A Number Of Insiders Buy CervoMed Stock
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
CERVOMED INC (CRVO) delivered earnings and revenue surprises of -23.53% and -69.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?